Activin A Receptor Type IB (ACVR1B) Antibody (Center) Blocking peptide
€293.00
In stock
SKU
AC-BP7801c
Background:
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. The gene for ACVR1B (activin A type IB receptor) is composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.
Other Names: Activin receptor type-1B, Activin receptor type IB, ACTR-IB, Activin receptor-like kinase 4, ALK-4, Serine/threonine-protein kinase receptor R2, SKR2, ACVR1B, ACVRLK4, ALK4
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7801c was selected from the Center region of human ACVR1B . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P36896
Gene ID: 91
Gene Name: ACVR1B
Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Bio References:
Harrison, C.A., et al., J. Biol. Chem. 278(23):21129-21135 (2003).Mukasa, C., et al., Endocrinology 144(4):1603-1611 (2003).Danila, D.C., et al., J. Clin. Endocrinol. Metab. 87(10):4741-4746 (2002).Schneider-Kolsky, M.E., et al., Placenta 23(4):294-302 (2002).Roijer, E., et al., Mamm. Genome 9(3):266-268 (1998).
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. The gene for ACVR1B (activin A type IB receptor) is composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.
Other Names: Activin receptor type-1B, Activin receptor type IB, ACTR-IB, Activin receptor-like kinase 4, ALK-4, Serine/threonine-protein kinase receptor R2, SKR2, ACVR1B, ACVRLK4, ALK4
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7801c was selected from the Center region of human ACVR1B . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P36896
Gene ID: 91
Gene Name: ACVR1B
Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Bio References:
Harrison, C.A., et al., J. Biol. Chem. 278(23):21129-21135 (2003).Mukasa, C., et al., Endocrinology 144(4):1603-1611 (2003).Danila, D.C., et al., J. Clin. Endocrinol. Metab. 87(10):4741-4746 (2002).Schneider-Kolsky, M.E., et al., Placenta 23(4):294-302 (2002).Roijer, E., et al., Mamm. Genome 9(3):266-268 (1998).
| Is Featured? | No |
|---|
Write Your Own Review